Genentech’s Evrysdi helped babies with SMA reach rare milestones in Phase II trial

Roche’s spinal muscular atrophy (SMA) drug Evrysdi (risdiplam) has helped pre-symptomatic babies reach rare milestones after two years of treatment in a Phase II trial.